Fulgent Genetics (FLGT) Operating Expenses (2015 - 2026)

Fulgent Genetics has disclosed Operating Expenses across 12 years of filings, most recently posting $56.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $56.1 million, up 16.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $229.9 million (up 24.04% YoY), and the FY2025 annual result was $222.0 million, up 22.55% from the prior year.
• Operating Expenses came in at $56.1 million for Q1 2026 at Fulgent Genetics, down from $68.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $176.4 million in Q4 2023 to a low of $39.6 million in Q3 2023.
• The 5-year median for Operating Expenses is $48.0 million (2024), against an average of $55.7 million.
• Across the five-year window, Operating Expenses surged 255.98% in 2023 and tumbled 72.79% in 2024, its largest moves.
• Fulgent Genetics' Operating Expenses stood at $49.5 million in 2022, then soared by 255.98% to $176.4 million in 2023, then plunged by 72.79% to $48.0 million in 2024, then surged by 43.42% to $68.8 million in 2025, then retreated by 18.47% to $56.1 million in 2026.
• The last three Operating Expenses figures came in at $56.1 million (Q1 2026), $68.8 million (Q4 2025), and $50.9 million (Q3 2025), per Business Quant data.